Efficacy of Nerve Blocks for Episodic Migraine
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT05734625
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bupivacaine HCl 0.5% Injectable Solution — DRUGWill receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
- Methylprednisolone 40 MG Injection — DRUGWill receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
Study Details
The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and preventing migraines. Our hypothesis is that the pain of most episodic migraine headaches can be eliminated and prevented for months by blocking the nerves that give pain sensation during a migraine.
Key Dates
- Start date
- Jul 10, 2023
- Status verified
- Mar 2026
- Primary completion
- Feb 28, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Greater Occipital Nerve block groupSubjects will receive bilateral greater occipital nerve blocks for a total of 2 blocks
- Experimental: Multiple Peripheral Nerve block groupSubjects will receive 10 nerve blocks to include bilateral greater occipital, lesser occipital, auriculotemporal, supraorbital and supratrochlear nerves.
Primary Outcome Measure
Elimination of acute headache [ Time Frame: 20 minutes after the last nerve intended for block ]
Central Contacts
- Family Medicine Research Study Coordinators507-422-6823
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | - |
Find similar trials in Rochester, MN
By condition
By specialty
By research site
Related Studies
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in AdultsPHASE2 · Recruiting · Ipsen · Birmingham, Alabama
- A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigrainePHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- A Study of Eptinezumab in Pediatric Participants With Episodic MigrainePHASE3 · Recruiting · H. Lundbeck A/S · Stamford, Connecticut
- Chiropractic Care for Episodic MigraineRecruiting · Brigham and Women's Hospital · Boston, Massachusetts